Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 8Neoplasms 6Head and Neck Neoplasms 6Prostatic Neoplasms 5Oropharyngeal Neoplasms 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Neoplasm Metastasis 4Myasthenia Gravis 4Lymphoma, Large B-Cell, Diffuse 4Cholangiocarcinoma 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Glioblastoma 3Fatigue 3Endometrial Neoplasms 3Carcinoma 3Breast Neoplasms 3Weight Loss 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2

Interventions

relatlimab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Muscle Invasive Bladder Urothelial Carcinoma × 30 days × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡